COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03839771




Registration number
NCT03839771
Ethics application status
Date submitted
6/02/2019
Date registered
15/02/2019
Date last updated
1/09/2021

Titles & IDs
Public title
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
Scientific title
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy.
Secondary ID [1] 0 0
2018-000451-41
Secondary ID [2] 0 0
HO150
Universal Trial Number (UTN)
Trial acronym
HOVON150AML
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Myeloid Leukemia 0 0
Myelodysplastic Syndrome With Excess Blasts-2 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders
Blood 0 0 0 0
Anaemia
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AG-120
Treatment: Drugs - Placebo for AG-120
Treatment: Drugs - AG-221
Treatment: Drugs - Placebo for AG-221

Placebo Comparator: Arm A: Placebo - Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |
The dosage for Placebo for AG-120 (IDH1): 500 mg dose/day
The dosage for Placebo for AG-221 (IDH2): 100mg dose/day

Experimental: Arm B: Ivosidenib (IDH1) or Enasidenib (IDH2) - Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |
The dosage for AG-120 (IDH1): 500 mg dose/day
The dosage for AG-221 (IDH2): 100mg dose/day


Treatment: Drugs: AG-120
250mg tablets

Treatment: Drugs: Placebo for AG-120
250mg tablets

Treatment: Drugs: AG-221
100mg tablets

Treatment: Drugs: Placebo for AG-221
100mg tablets

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Event-free survival (EFS) - EFS is defined as the time from randomization to failure to achieve CR or CRi after remission induction, death after achieving CR or CRi or relapse after achieving CR or CRi, whichever occurs first. A patient is said to have failed to achieve CR or CRi after induction therapy, if his/her best response during or at completion of the induction treatment is less than CRi. Patients who achieved CR/CRi after remission induction and are not known to have relapsed or died will be censored at the date of last clinical assessment.
Timepoint [1] 0 0
Approximately up to 60 months following first patient enrollment
Secondary outcome [1] 0 0
Overall survival (OS) - OS is defined as the time from date of randomization to date of death due to any cause. Patients still alive or lost to follow up will be censored at the time they were last known to be alive.
Timepoint [1] 0 0
Approximately up to 84 months following first patient enrollment
Secondary outcome [2] 0 0
Relapse-free survival (RFS) after CR/CRi - RFS is defined as time from the date of achievement of CR/CRi until relapse or death from any cause, whichever comes first. Patients still in first CR/CRi and alive or lost to follow up will be censored at the date of last clinical assessment.
Timepoint [2] 0 0
Approximately up to 60 months following first patient enrollment
Secondary outcome [3] 0 0
Cumulative incidence of relapse (CIR) after CR/CRi - CIR is measured from the date of achievement of CR/CRi until the date of relapse. Patients not known to have relapsed will be censored on the date of last clinical assessment. Patients who died without relapse will be counted as a competing cause of failure.
Timepoint [3] 0 0
Approximately up to 60 months following first patient enrollment
Secondary outcome [4] 0 0
Cumulative incidence of death (CID) after CR/CRi - CID is measured from the date of achievement of CR/CRi until the date of death from any cause. Patients not known to have died will be censored on the date they were last known to be alive. Patients who experienced relapse in CR/CRi will be counted as competing cause of failure.
Timepoint [4] 0 0
Approximately up to 60 months following first patient enrollment
Secondary outcome [5] 0 0
Complete remission without minimal residual disease (CRMRD-) rate after induction cycle 2 - CRMRD- rate is defined as the percentage of patients who achieved CR or CRi with no evidence of MRD in bone marrow
Timepoint [5] 0 0
Approximately up to 60 months following first patient enrollment
Secondary outcome [6] 0 0
Frequency and severity of adverse events according to CTCAE version 5.0 - Adverse events will be evaluated using the National Cancer Institute's Common Terminology Criteria for AEs (CTCAE) version 5.0
Timepoint [6] 0 0
Continuously throughout the study, starting from informed consent until 30 days following the last administration of any study drug
Secondary outcome [7] 0 0
CR/CRi rates after induction cycle 1 and 2 - CR and CRi are determined by the Investigator based on the European LeukemiaNet (ELN2017) recommended response criteria
Timepoint [7] 0 0
Approximately up to 60 months following first patient enrollment
Secondary outcome [8] 0 0
CR/CRi rate after remission induction (i.e., CR or CRi as best response during or at completion of induction therapy) - CR+CRi rate after remission induction is defined as the percentage of patients with best response of CR or CRi during or at completion of induction therapy
Timepoint [8] 0 0
Approximately up to 60 months following first patient enrollment
Secondary outcome [9] 0 0
Time to hematopoietic recovery after each chemotherapy treatment cycle - Time to hematopoietic recovery is defined as the time from the start of the cycle until recovery
Timepoint [9] 0 0
Approximately up to 60 months following first patient enrollment
Secondary outcome [10] 0 0
EQ-5D-5L visual analogue scale (VAS) - The EQ-5D-5L is a 5 item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today". Each domain has 5 levels. Each level has a 1 digit number expressing the level selected for that dimension. These levels are summed up and the self-rated health is recorded on a 20 cm vertical, visual analogue scale, with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'.
Timepoint [10] 0 0
At entry, 1st day of maintenance, every 3 months during the first year of maintenance, every 6 months during the second year of maintenance until relapse or treatment discontinuation (approximately up to 84 months following first patient enrollment)
Secondary outcome [11] 0 0
EORTC-QLQ-C30 global health status/QoL scale. - The EORTC QLQ-C30 is a 30-item questionnaire that assesses 5 functional subdomains (physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning), 1 global health status, 3 symptom subdomains (fatigue, nausea and vomiting and pain) and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Estimate the average of the items that contribute to the scale; this is the raw score. a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.
Timepoint [11] 0 0
At entry, 1st day of maintenance, every 3 months during the first year of maintenance, every 6 months during the second year of maintenance until relapse or treatment discontinuation (approximately up to 84 months following first patient enrollment)

Eligibility
Key inclusion criteria
- Age =18 years

- Newly diagnosed AML or MDS-EB2 defined according to WHO criteria, with a documented
IDH1 or IDH2 gene mutation (as determined by the clinical trial assay) at a specific
site (IDH1 R132, IDH2 R140, IDH2 R172). AML may be secondary to prior hematological
disorders, including MDS, and/or therapy-related (in which prior disease should have
been documented to have existed for at least 3 months). Patients may have had previous
treatment with hypomethylating agents (HMAs) for MDS. HMAs have to be stopped at least
four weeks before registration

- Patients with dual mutant FLT3 and IDH1 or IDH2 mutations may be enrolled only if, for
medical or other reasons, treatment with a FLT3 inhibitor is not considered.

- Considered to be eligible for intensive chemotherapy.

- ECOG/WHO performance status = 2

- Adequate hepatic function as evidenced by:

- Serum total bilirubin = 2.5 × upper limit of normal (ULN) unless considered due
to Gilbert's disease (e.g. a mutation in UGT1A1) (only for patients in IDH2
cohort), or leukemic involvement of the liver - following written approval by the
(Co)Principal Investigator.

- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline
phosphatase (ALP) = 3.0 × ULN, unless considered due to leukemic involvement of
the liver, following written approval by the Principal Investigator.

- Adequate renal function as evidenced by creatinine clearance > 40 mL/min based on the
Cockroft-Gault formula for glomerular filtration rate (GFR).

- Able to understand and willing to sign an informed consent form (ICF).

- Written informed consent

Female patient must either:

o Be of nonchildbearing potential: Postmenopausal (defined as at least 1 year without any
menses) prior to screening, or Documented surgically sterile or status posthysterectomy (at
least 1 month prior to screening)

o Or, if of childbearing potential: Agree not to try to become pregnant during the study
and for 6 months after the final study drug administration And have a negative urine or
serum pregnancy test at screening And, if heterosexually active, agree to consistently use
highly effective* contraception per locally accepted standards in addition to a barrier
method starting at screening and throughout the study period and for 6 months after the
final study drug administration.

- Highly effective forms of birth control include:

- Consistent and correct usage of established hormonal contraceptives that inhibit
ovulation,

- Established intrauterine device (IUD) or intrauterine system (IUS),

- Bilateral tubal occlusion,

- Vasectomy (A vasectomy is a highly effective contraception method provided the
absence of sperm has been confirmed. If not, an additional highly effective
method of contraception should be used.)

- Male is sterile due to a bilateral orchiectomy.

- Sexual abstinence is considered a highly effective method only if defined as
refraining from heterosexual activity during the entire period of risk associated
with the study drug. The reliability of sexual abstinence needs to be evaluated
in relation to the duration of the clinical study and the preferred and usual
lifestyle of the patient.

- List is not all inclusive. Prior to enrollment, the investigator is responsible for
confirming patient will utilize highly effective forms of birth control per the
requirements of the CTFG Guidance document 'Recommendations related to contraception
and pregnancy testing in clinical trials', September 2014 (and any updates thereof)
during the protocol defined period.

- Female patient must agree not to breastfeed starting at screening and throughout
the study period, and for 2 months and 1 week after the final study drug
administration.

- Female patient must not donate ova starting at screening and throughout the study
period, and for 6 months after the final study drug administration.

- Male patient and their female partners who are of childbearing potential
must be using highly effective contraception per locally accepted standards
in addition to a barrier method starting at screening and continue
throughout the study period and for 4 months and 1 week after the final
study drug administration

- Male patient must not donate sperm starting at screening and throughout the
study period and for 4 months and 1 week after the final study drug
administration.

- Subject agrees not to participate in another interventional study while
on treatment
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior chemotherapy for AML or MDS-EB2 (with the exception of HMA). Hydroxyurea is
allowed for the control of peripheral leukemic blasts in patients with leukocytosis
(e.g., white blood cell [WBC] counts > 30x109/L).

- Dual IDH1 and IDH2 mutations.

- Acute promyelocytic leukemia (APL) with PML-RARA or one of the other pathognomonic
variant fusion genes/chromosome translocations.

- Blast crisis after chronic myeloid leukemia (CML).

- Known allergy or suspected hypersensitivity to Ivosidenib or Enasidenib and/or any
exipients.

- Taking medications with narrow therapeutic windows with potential interaction with
investigational medication (see Appendix I), unless the patient can be transferred to
other medications prior to enrolling or unless the medications can be properly
monitored during the study.

- Taking P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP)
transporter-sensitive substrate medications (see Appendix J) unless the patient can be
transferred to other medications within = 5 half-lives prior to administration of
ivosidenib or enasidenib, or unless the medications can be properly monitored during
the study.

- Breast feeding at the start of study treatment.

- Active infection, including hepatitis B or C or HIV infection that is uncontrolled at
randomization. An infection controlled with an approved or closely monitored
antibiotic/antiviral/antifungal treatment is allowed.

- Patients with a currently active second malignancy. Patients are not considered to
have a currently active malignancy if they have completed therapy and are considered
by their physician to be at < 30% risk of relapse within one year. However, patients
with the following history/concurrent conditions are allowed:

- Basal or squamous cell carcinoma of the skin

- Carcinoma in situ of the cervix

- Carcinoma in situ of the breast

- Incidental histologic finding of prostate cancer

- Significant active cardiac disease within 6 months prior to the start of study
treatment, including New York Heart Association (NYHA) Class III or IV congestive
heart failure (appendix G); myocardial infarction, unstable angina and/or stroke; or
left ventricular ejection fraction (LVEF) < 40% by ultrasound or MUGA scan obtained
within 28 days prior to the start of study treatment.

- QTc interval using Fridericia's formula (QTcF) = 450 msec or other factors that
increase the risk of QT prolongation or arrhythmic events (e.g., heart failure,family
history of long QT interval syndrome). Prolonged QTc interval associated with bundle
branch block or pacemaking is permitted with written approval of the Principal
Investigator.

- Taking medications that are known to prolong the QT interval (see Appendix K), unless
deemed critical and without a suitable alternative. In those cases, they may be
administered, but with proper monitoring (see section 10.2, Table 13).

- Dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the
ingestion or gastrointestinal absorption of orally administered drugs.

- Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known
CNS leukemia. Evaluation of cerebrospinal fluid (CSF) during screening is only
required if there is a clinical suspicion of CNS involvement by leukemia during
screening.

- A known medical history of progressive multifocal leukoencephalopathy (PML).

- Immediately life-threatening, severe complications of leukemia such as uncontrolled
bleeding, pneumonia with hypoxia or shock, and/or severe disseminated intravascular
coagulation

- Any other medical condition deemed by the Investigator to be likely to interfere with
a patient's ability to give informed consent or participate in the study.

- Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol and follow-up schedule.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
AU-Adelaide-FLINDERS - Adelaide
Recruitment hospital [2] 0 0
AU-Adelaide-RAH - Adelaide
Recruitment hospital [3] 0 0
AU-Brisbane-PAH - Brisbane
Recruitment hospital [4] 0 0
AU-Camperdown-RPA - Camperdown
Recruitment hospital [5] 0 0
AU-Canberra-CANBERRAHOSPITAL - Canberra
Recruitment hospital [6] 0 0
AU-Douglas-TOWNSVILLE - Douglas
Recruitment hospital [7] 0 0
AU-Hobart TAS-RHOBART - Hobart
Recruitment hospital [8] 0 0
AU-Launceston TAS-LAUNCESTON - Launceston
Recruitment hospital [9] 0 0
AU-Melbourne-ALFRED - Melbourne
Recruitment hospital [10] 0 0
AU-Melbourne-AUSTIN - Melbourne
Recruitment hospital [11] 0 0
AU-Melbourne-MONASH - Melbourne
Recruitment hospital [12] 0 0
AU-Melbourne-RMELBOURNE - Melbourne
Recruitment hospital [13] 0 0
AU-Melbourne-SVHM - Melbourne
Recruitment hospital [14] 0 0
AU-Perth-FSH - Perth
Recruitment hospital [15] 0 0
AU-Perth-RPH - Perth
Recruitment hospital [16] 0 0
AU-Perth-SCGH - Perth
Recruitment hospital [17] 0 0
AU-Sydney-CONCORD - Sydney
Recruitment hospital [18] 0 0
AU-Sydney-RNSH - Sydney
Recruitment hospital [19] 0 0
AU-Sydney-SVHS - Sydney
Recruitment hospital [20] 0 0
AU-Sydney-WSAH - Sydney
Recruitment hospital [21] 0 0
AU-Waratah-CALVARYMATER - Waratah
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Brisbane
Recruitment postcode(s) [3] 0 0
- Camperdown
Recruitment postcode(s) [4] 0 0
- Canberra
Recruitment postcode(s) [5] 0 0
- Douglas
Recruitment postcode(s) [6] 0 0
- Hobart
Recruitment postcode(s) [7] 0 0
- Launceston
Recruitment postcode(s) [8] 0 0
- Melbourne
Recruitment postcode(s) [9] 0 0
- Perth
Recruitment postcode(s) [10] 0 0
- Sydney
Recruitment postcode(s) [11] 0 0
- Waratah
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Graz
Country [2] 0 0
Austria
State/province [2] 0 0
Innsbruck
Country [3] 0 0
Austria
State/province [3] 0 0
Linz
Country [4] 0 0
Austria
State/province [4] 0 0
Vienna
Country [5] 0 0
Belgium
State/province [5] 0 0
Antwerpen
Country [6] 0 0
Belgium
State/province [6] 0 0
Brugge
Country [7] 0 0
Belgium
State/province [7] 0 0
Brussels
Country [8] 0 0
Belgium
State/province [8] 0 0
Gent
Country [9] 0 0
Belgium
State/province [9] 0 0
Haine-Saint-Paul
Country [10] 0 0
Belgium
State/province [10] 0 0
Hasselt
Country [11] 0 0
Belgium
State/province [11] 0 0
Leuven
Country [12] 0 0
Belgium
State/province [12] 0 0
Liège
Country [13] 0 0
Belgium
State/province [13] 0 0
Roeselare
Country [14] 0 0
Belgium
State/province [14] 0 0
Yvoir
Country [15] 0 0
Estonia
State/province [15] 0 0
Tartu
Country [16] 0 0
Finland
State/province [16] 0 0
Helsinki
Country [17] 0 0
Finland
State/province [17] 0 0
Tampere
Country [18] 0 0
France
State/province [18] 0 0
Amiens
Country [19] 0 0
France
State/province [19] 0 0
Angers
Country [20] 0 0
France
State/province [20] 0 0
Argenteuil
Country [21] 0 0
France
State/province [21] 0 0
Bayonne
Country [22] 0 0
France
State/province [22] 0 0
Besançon
Country [23] 0 0
France
State/province [23] 0 0
Bobigny
Country [24] 0 0
France
State/province [24] 0 0
Chambéry
Country [25] 0 0
France
State/province [25] 0 0
Chesnay
Country [26] 0 0
France
State/province [26] 0 0
Clamart
Country [27] 0 0
France
State/province [27] 0 0
Clermont-Ferrand
Country [28] 0 0
France
State/province [28] 0 0
Créteil
Country [29] 0 0
France
State/province [29] 0 0
Grenoble cedex 9
Country [30] 0 0
France
State/province [30] 0 0
Lens
Country [31] 0 0
France
State/province [31] 0 0
Lille
Country [32] 0 0
France
State/province [32] 0 0
Limoges
Country [33] 0 0
France
State/province [33] 0 0
Lyon
Country [34] 0 0
France
State/province [34] 0 0
Marseille
Country [35] 0 0
France
State/province [35] 0 0
Montpellier
Country [36] 0 0
France
State/province [36] 0 0
Mulhouse
Country [37] 0 0
France
State/province [37] 0 0
Nantes
Country [38] 0 0
France
State/province [38] 0 0
Nice
Country [39] 0 0
France
State/province [39] 0 0
Orléans
Country [40] 0 0
France
State/province [40] 0 0
Paris
Country [41] 0 0
France
State/province [41] 0 0
Pessac
Country [42] 0 0
France
State/province [42] 0 0
Poitiers
Country [43] 0 0
France
State/province [43] 0 0
Reims
Country [44] 0 0
France
State/province [44] 0 0
Rennes
Country [45] 0 0
France
State/province [45] 0 0
Rouen
Country [46] 0 0
France
State/province [46] 0 0
Strasbourg
Country [47] 0 0
France
State/province [47] 0 0
Toulouse
Country [48] 0 0
France
State/province [48] 0 0
Tours
Country [49] 0 0
France
State/province [49] 0 0
VandÅ“uvre-lès-Nancy
Country [50] 0 0
France
State/province [50] 0 0
Villejuif
Country [51] 0 0
Germany
State/province [51] 0 0
Bad Saarow
Country [52] 0 0
Germany
State/province [52] 0 0
Berlin
Country [53] 0 0
Germany
State/province [53] 0 0
Bochum
Country [54] 0 0
Germany
State/province [54] 0 0
Bonn
Country [55] 0 0
Germany
State/province [55] 0 0
Braunschweig
Country [56] 0 0
Germany
State/province [56] 0 0
Bremen
Country [57] 0 0
Germany
State/province [57] 0 0
Dortmund
Country [58] 0 0
Germany
State/province [58] 0 0
Düsseldorf
Country [59] 0 0
Germany
State/province [59] 0 0
Essen
Country [60] 0 0
Germany
State/province [60] 0 0
Esslingen
Country [61] 0 0
Germany
State/province [61] 0 0
Flensburg
Country [62] 0 0
Germany
State/province [62] 0 0
Gießen
Country [63] 0 0
Germany
State/province [63] 0 0
Goch
Country [64] 0 0
Germany
State/province [64] 0 0
Hamburg
Country [65] 0 0
Germany
State/province [65] 0 0
Hamm
Country [66] 0 0
Germany
State/province [66] 0 0
Hanau
Country [67] 0 0
Germany
State/province [67] 0 0
Hannover
Country [68] 0 0
Germany
State/province [68] 0 0
Herne
Country [69] 0 0
Germany
State/province [69] 0 0
Homburg
Country [70] 0 0
Germany
State/province [70] 0 0
Karlsruhe
Country [71] 0 0
Germany
State/province [71] 0 0
Lebach
Country [72] 0 0
Germany
State/province [72] 0 0
Lemgo
Country [73] 0 0
Germany
State/province [73] 0 0
Ludwigshafen
Country [74] 0 0
Germany
State/province [74] 0 0
Lüdenscheid
Country [75] 0 0
Germany
State/province [75] 0 0
Magdeburg
Country [76] 0 0
Germany
State/province [76] 0 0
Mainz
Country [77] 0 0
Germany
State/province [77] 0 0
Meschede
Country [78] 0 0
Germany
State/province [78] 0 0
Minden
Country [79] 0 0
Germany
State/province [79] 0 0
München
Country [80] 0 0
Germany
State/province [80] 0 0
Offenburg
Country [81] 0 0
Germany
State/province [81] 0 0
Oldenburg
Country [82] 0 0
Germany
State/province [82] 0 0
Passau
Country [83] 0 0
Germany
State/province [83] 0 0
Stuttgart
Country [84] 0 0
Germany
State/province [84] 0 0
Traunstein
Country [85] 0 0
Germany
State/province [85] 0 0
Trier
Country [86] 0 0
Germany
State/province [86] 0 0
Tübingen
Country [87] 0 0
Germany
State/province [87] 0 0
Ulm
Country [88] 0 0
Germany
State/province [88] 0 0
Villingen-Schwenningen
Country [89] 0 0
Germany
State/province [89] 0 0
Wuppertal
Country [90] 0 0
Ireland
State/province [90] 0 0
Cork
Country [91] 0 0
Ireland
State/province [91] 0 0
Dublin
Country [92] 0 0
Ireland
State/province [92] 0 0
Galway
Country [93] 0 0
Lithuania
State/province [93] 0 0
Vilnius
Country [94] 0 0
Luxembourg
State/province [94] 0 0
Luxembourg
Country [95] 0 0
Netherlands
State/province [95] 0 0
Amersfoort
Country [96] 0 0
Netherlands
State/province [96] 0 0
Amsterdam
Country [97] 0 0
Netherlands
State/province [97] 0 0
Arnhem
Country [98] 0 0
Netherlands
State/province [98] 0 0
Breda
Country [99] 0 0
Netherlands
State/province [99] 0 0
Delft
Country [100] 0 0
Netherlands
State/province [100] 0 0
Den Bosch
Country [101] 0 0
Netherlands
State/province [101] 0 0
Den Haag
Country [102] 0 0
Netherlands
State/province [102] 0 0
Dordrecht
Country [103] 0 0
Netherlands
State/province [103] 0 0
Eindhoven
Country [104] 0 0
Netherlands
State/province [104] 0 0
Enschede
Country [105] 0 0
Netherlands
State/province [105] 0 0
Groningen
Country [106] 0 0
Netherlands
State/province [106] 0 0
Leeuwarden
Country [107] 0 0
Netherlands
State/province [107] 0 0
Leiden
Country [108] 0 0
Netherlands
State/province [108] 0 0
Maastricht
Country [109] 0 0
Netherlands
State/province [109] 0 0
Nieuwegein
Country [110] 0 0
Netherlands
State/province [110] 0 0
Nijmegen
Country [111] 0 0
Netherlands
State/province [111] 0 0
Rotterdam
Country [112] 0 0
Netherlands
State/province [112] 0 0
Utrecht
Country [113] 0 0
Netherlands
State/province [113] 0 0
Zwolle
Country [114] 0 0
Norway
State/province [114] 0 0
Bergen
Country [115] 0 0
Norway
State/province [115] 0 0
Oslo
Country [116] 0 0
Norway
State/province [116] 0 0
Stavanger
Country [117] 0 0
Norway
State/province [117] 0 0
Tromsø
Country [118] 0 0
Norway
State/province [118] 0 0
Trondheim
Country [119] 0 0
Spain
State/province [119] 0 0
Barcelona
Country [120] 0 0
Spain
State/province [120] 0 0
Girona
Country [121] 0 0
Spain
State/province [121] 0 0
Madrid
Country [122] 0 0
Spain
State/province [122] 0 0
Palma
Country [123] 0 0
Spain
State/province [123] 0 0
Tarragona
Country [124] 0 0
Spain
State/province [124] 0 0
Valencia
Country [125] 0 0
Sweden
State/province [125] 0 0
Lund
Country [126] 0 0
Sweden
State/province [126] 0 0
Stockholm
Country [127] 0 0
Sweden
State/province [127] 0 0
Uppsala
Country [128] 0 0
Switzerland
State/province [128] 0 0
Basel
Country [129] 0 0
Switzerland
State/province [129] 0 0
Bellinzona
Country [130] 0 0
Switzerland
State/province [130] 0 0
Bern
Country [131] 0 0
Switzerland
State/province [131] 0 0
Fribourg
Country [132] 0 0
Switzerland
State/province [132] 0 0
Geneve
Country [133] 0 0
Switzerland
State/province [133] 0 0
Lausanne
Country [134] 0 0
Switzerland
State/province [134] 0 0
Luzern
Country [135] 0 0
Switzerland
State/province [135] 0 0
Saint Gallen
Country [136] 0 0
Switzerland
State/province [136] 0 0
Zürich

Funding & Sponsors
Primary sponsor type
Other
Name
Stichting Hemato-Oncologie voor Volwassenen Nederland
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
AML and MDS-EB2 are malignancies of the bone marrow. The standard treatment for these
diseases is chemotherapy. Patients participating have a special type of this disease because
the leukemia cells (blasts) have developed an error in the genetic material (DNA). This error
is called an IDH1 mutation or an IDH2 mutation (a mutation is a change in the DNA), which
leads to changes in specific substances in the leukemia cells. This trial will investigate
whether the addition of the new drugs Ivosidenib (for patients with IDH1 mutation) or
Enasidenib (for patients with IDH2 mutation) to the standard treatment of chemotherapy
controle the disease more effectively and for a longer period.
Trial website
https://clinicaltrials.gov/show/NCT03839771
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
B.J. Wouters
Address 0 0
Erasmus MC / HOVON
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
B.J. Wouters, Dr.
Address 0 0
Country 0 0
Phone 0 0
+31 10 704 15 60
Fax 0 0
Email 0 0
b.wouters@erasmusmc.nl
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03839771